Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a potent endothelial cell mitogen which mediates its effects by binding to tyrosine kinase receptors. We have characterized the VEGF-activated intracellular signal transduction pathway in bovine aortic endothelial cells and correlated this to its mitogenic effects. VEGF induced concentration- and time-dependent increases in protein kinase C (PKC) activation with a maximum of 2.2-fold above the basal level at 5 x 10(-10) M within 10 min as measured both by in situ and translocation assays. Immunoblotting analysis of PKC isoforms in cytosolic and membrane fractions indicated that after VEGF stimulation the content of Ca(2+)-sensitive PKC isoforms (alpha and betaII) was increased in the membrane fractions, whereas no changes were observed for PKC isoforms delta and epsilon. The stimulation of PKC activity by VEGF was preceded by the activation of phospholipase Cgamma (PLCgamma). This was demonstrated by parallel increases in PLCgamma tyrosine phosphorylation, [3H]inositol phosphate production, and [3H]arachidonic acid-labeled diacylglycerol formation in bovine aortic endothelial cells. In addition, VEGF increased phosphatidylinositol 3-kinase activity 2.1-fold which was inhibited by wortmannin, a phosphatidylinositol 3-kinase inhibitor, without decreasing the VEGF-induced increase in PKC activity or endothelial cell growth. Interestingly, genistein, a tyrosine kinase inhibitor, and GFX or H-7, PKC inhibitors, abolished both VEGF-induced PKC activation and endothelial cell proliferation. VEGF's mitogenic effect was inhibited by a PKC isoform beta-selective inhibitor, LY333531, in a concentration-dependent manner. In contrast, antisense PKC-alpha oligonucleotides enhanced VEGF-stimulated cell growth with a simultaneous decrease of 70% in PKC-alpha protein content. Thus, VEGF appears to mediate its mitogenic effects partly through the activation of the PLCgamma and PKC pathway, involving predominately PKC-beta isoform activation in endothelial cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, within the TME, PKC beta, another PKC isoform, is a well‐documented effector of the VEGF signaling that promotes angiogenesis and is required for invasiveness in certain tumors, such as pancreatic tumors [122, 123, 124].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [122]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302 · cited 2×
“and assayed by the method of Bradford (19).”
MethodInfluentialA RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · cited 1×
“The cells were scraped and total lipids were extracted with chloroform according to the methods of Bligh and Dyer (22).”
MethodVascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 2×
“VEGF was independently isolated as both an endothelial cell growth factor (1) and as a vasopermeability factor (3).”
BackgroundVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Intracellular Signaling by Hydrolysis of Phospholipids and Activation of Protein Kinase C
Nishizuka, Y. (1992) · Science · doi:10.1126/science.1411571 · Cited by 4,472 · cited 4×
“In contrast, PKC isoforms e and d, which lack Ca(21) binding sites, are only responsive to DAG and did not translocate adequately for our antibodies to detect (25).”
BackgroundMethodInfluentialAiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793 · cited 2×
“Physiologically, elevated levels of VEGF have been associated with tumor angiogenesis (7) and hypoxia-induced proliferative ocular disorders such as diabetic proliferative retinopathy and retinal vein occlusion (8, 9).”
BackgroundSelf-citationGenistein, a specific inhibitor of tyrosine-specific protein kinases.
Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., & Fukami, Y. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45614-1 · Cited by 3,724 · cited 1×
“The addition of genistein (40 mm), a tyrosine kinase inhibitor (27), significantly reduced the VEGF-induced tyrosine phosphorylation of PLCg.”
BackgroundOncogenes and signal transduction
Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., & Soltoff, S. (1991) · Cell · doi:10.1016/0092-8674(91)90639-g · Cited by 2,694 · cited 2×
“Since PI 3-kinase has been shown to be associated with several different tyrosine kinase receptors (29), and VEGF has been reported to increase PI 3-kinase tyrosine phosphorylation (12, 13), we determined whether PI 3-kinase activity could also be activated by VEGF.”
BackgroundThe bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C
Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., & Loriolle, F. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98476-0 · Cited by 2,456
Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992) · Nature · doi:10.1038/359845a0 · Cited by 2,275 · cited 1×
“Physiologically, elevated levels of VEGF have been associated with tumor angiogenesis (7) and hypoxia-induced proliferative ocular disorders such as diabetic proliferative retinopathy and retinal vein occlusion (8, 9).”
Background
Cited by
Items 101–200 of 615
Ellis, E. A., Guberski, D. L., Somogyi-Mann, M., & Grant, M. B. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00216-6 · Cited by 165
Filicori, M., Fazleabas, A. T., Huhtaniemi, I., Licht, P., Rao, C. V., Tesarik, J., & Zygmunt, M. (2005) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.02.033 · Cited by 163
Targets for pharmacological intervention of endothelial hyperpermeability and barrier function.
Amerongen, G. P. V. N., & van Hinsbergh, V. (2002) · Vascular Pharmacology · doi:10.1016/s1537-1891(03)00014-4 · Cited by 109
Thallas-Bonke, V., Lindschau, C., Rizkalla, B., Bach, L. A., Boner, G., Meier, M., Haller, H., Cooper, M. E., & Forbes, J. M. (2004) · Diabetes · doi:10.2337/diabetes.53.11.2921 · Cited by 152
“Our results showed that ALT-711 has the ability to reduce other PKC isoforms, possibly linked with the ability of VEGF to activate several isoforms, including PKC- , - I, - II (38,39), and -ε (40), or the regulation of other PKC isoforms by PKC- .”
BackgroundBerndt, S., Perrier d'Hauterive, S., Blacher, S., Péqueux, C., Lorquet, S., Munaut, C., Applanat, M., Astrid Hervé, M., Lamandé, N., Corvol, P., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-5885fje · Cited by 161
Oh, H., Takagi, H., Otani, A., Koyama, S., Kemmochi, S., Uemura, A., & Honda, Y. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012074399 · Cited by 161
Self-citationStructure and Function of Vascular Endothelial Growth Factor Receptor-1 and -2
Shibuya, M., Ito, N., & Claesson-Welsh, L. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_4 · Cited by 159
Sakaue-Sawano, A., Takahashi, T., Yamaguchi, S., & Shibuya, M. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7327 · Cited by 152
Angiogenesis in Embryos and Ischemic Diseases
Breier, G., Damert, A., Plate, K. H., & Risau, W. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1657611 · Cited by 130
NADPH Oxidase Activity Selectively Modulates Vascular Endothelial Growth Factor Signaling Pathways
Abid, M. R., Spokes, K. C., Shih, S.-C., & Aird, W. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702175200 · Cited by 150
Vascular Endothelial Growth Factor Activates STAT Proteins in Aortic Endothelial Cells
Bartoli, M., Gu, X., Tsai, N. T., Venema, R. C., Brooks, S. E., Marrero, M. B., & Caldwell, R. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000318200 · Cited by 136
Vascular endothelial growth factor
Zachary, I. C. (1998) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(98)00082-x · Cited by 147
Vascular endothelial growth factor receptor‐2: Its unique signaling and specific ligand, VEGF‐E
Shibuya, M. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01514.x · Cited by 146
Diabetic retinopathy: An update
Gupta, A., Singh, R., Ramasamy, K., Abraham, C., & Gupta, V. (2008) · Indian Journal of Ophthalmology · doi:10.4103/0301-4738.40355 · Cited by 143
Vascular Endothelial Growth Factor and Microvascular Permeability
Bates, D. O., Lodwick, D., & Williams, B. (1999) · Microcirculation · doi:10.1111/j.1549-8719.1999.tb00091.x · Cited by 143
“These have been termed VEGF-B (79), VEGF-C (47) [also called VEGF related protein, VRP (58)], VEGF-D (114) [also called c-fos induced growth factor, FIGF (81)], VEGFE and Placental Growth Factor (PlGF) (65).”
BackgroundInfluentialVEGFR and Type-V RTK Activation and Signaling
Shibuya, M. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009092 · Cited by 120
“Our study and previous studies have found that PKCs, particularly PKC-b, play an important role in VEGFR2 signaling (Xia et al. 1996; Takahashi and Shibuya 1997; Takahashi et al. 1999).”
ResultHata, Y., Duh, E. J., Zhang, K., Robinson, G. S., & Aiello, L. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.19294 · Cited by 142
Self-citationOxidants in Receptor Tyrosine Kinase Signal Transduction Pathways
Aslan, M., & Özben, T. (2003) · Antioxidants & Redox Signaling · doi:10.1089/152308603770380089 · Cited by 125
“Ang II, angiotensin II; AT1 and AT2, angiotensin 1 and 2 receptor, respectively; DPI, diphenylene iodonium; EGF, epidermal growth factor; ERK, extracellular signal-regulated kinase; FGF, fibroblast growth factor; FRS2 (SNT), FGF receptor-stimulated 2 binding protein; Grb2, receptor-bound protein 2; Ig, immunoglobulin;…”
InfluentialProtein kinase Cα: disease regulator and therapeutic target
Konopatskaya, O., & Poole, A. W. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.10.006 · Cited by 136
“Although there are some reports to the contrary [20, 21 ], PKCa has generally been shown to be a positive regulator of angiogenesis [22], involving the processes of endothelial cell migration, adhesion and tube formation mediated by vascular endothelial growth factor”
ResultOvercoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
Kawata, H., Yoshida, K., Kawamoto, A., Kurioka, H., 高瀬, 栄., Sasaki, Y., Hatanaka, K., Kobayashi, M., Ueyama, T., Hashimoto, T., et al. (2001) · Circulation Research · doi:10.1161/hh0701.088842 · Cited by 135
Ramana, K. V., Friedrich, B. M., Tammali, R., West, M., Bhatnagar, A., & Sk, S. (2005) · Diabetes · doi:10.2337/diabetes.54.3.818 · Cited by 133
Eriksson, A., Cao, R., Roy, J., Tritsaris, K., Wahlestedt, C., Dissing, S., Thyberg, J., & Cao, Y. (2003) · Circulation · doi:10.1161/01.cir.0000055324.34758.32 · Cited by 121
Gliki, G., Wheeler-Jones, C. P. D., & Zachary, I. C. (2002) · Cell Biology International · doi:10.1016/s1065-6995(02)90926-1 · Cited by 131
Protein kinase C-α mediates endothelial barrier dysfunction induced by TNF-α
Ferro, T., Neumann, P., Gertzberg, N., Clements, R., & Johnson, A. (2000) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2000.278.6.l1107 · Cited by 119
“Translation of PKC-a RNA was inhibited using a phosphorothioated PKC-a antisense oligonucleotide (Promega; Madison, WI) complementary to a region two bases upstream from the initiation codon of PKC-a [nucleotide 49 58-GTC CCT CGC CGC CTC CTG-38 nucleotide 32 (44)].”
MethodChang, Y. S., Munn, L. L., Hillsley, M., Dull, R. O., Yuan, J., Lakshminarayanan, S., Gardner, T. W., Jain, R. K., & Tarbell, J. M. (2000) · Microvascular Research · doi:10.1006/mvre.1999.2225 · Cited by 130
Protein kinase C activation and its pharmacological inhibition in vascular disease
Meier, M., & King, G. L. (2000) · Vascular Medicine · doi:10.1177/1358836x0000500307 · Cited by 126
Self-citationXu, H., Czerwinski, P., Hortmann, M., Sohn, H.-Y., Förstermann, U., & Li, H. (2007) · Cardiovascular Research · doi:10.1093/cvr/cvm085 · Cited by 129
Mason, J. C., Yarwood, H., Sugars, K., Morgan, B. P., Davies, K. A., & Haskard, D. O. (1999) · Blood · doi:10.1182/blood.v94.5.1673.417a05_1673_1682 · Cited by 111
Angiogenic Functions of Voltage-gated Na+ Channels in Human Endothelial Cells
Andrikopoulos, P., Fraser, S. P., Patterson, L., Ahmad, Z., Burcu, H., Ottaviani, D., Diss, J. K. J., Box, C., Eccles, S. A., & Djamgoz, M. B. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.187559 · Cited by 123
Karagulova, G., Yue, Y., Moreyra, A. E., Boutjdir, M., & Korichneva, I. L. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119644 · Cited by 123
Badr, G. A., Tang, J., Ismail-Beigi, F., & Kern, T. S. (2000) · Diabetes · doi:10.2337/diabetes.49.6.1016 · Cited by 112
Growth factor signaling pathways in vascular development
Tallquist, M. D., Soriano, P. M., & Klinghoffer, R. A. (1999) · Oncogene · doi:10.1038/sj.onc.1203216 · Cited by 123
“Importantly, stimulation of endothelial cells with VEGF leads to an increase in PLCg enzymatic activity (Xia et al., 1996).”
BackgroundAssociation of Inflammatory Factors With Macular Edema in Branch Retinal Vein Occlusion
Noma, H., Mimura, T., & Eguchi, S. (2013) · JAMA Ophthalmology · doi:10.1001/2013.jamaophthalmol.228 · Cited by 121
Genesis and pathogenesis of lymphatic vessels
Jeltsch, M., Tammela, T., Alitalo, K. K., & Wilting, J. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0777-2 · Cited by 120
“Akt phosphorylation by PI3 kinase seems to be important for survival signaling (Xia et al. 1996; Gerber et al. 1998b; Jiang et al. 2000).”
BackgroundCytokines and Pathogenesis of Central Retinal Vein Occlusion
Noma, H., Yasuda, K., & Shimura, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113457 · Cited by 119
Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema
Noma, H., Yasuda, K., & Shimura, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073427 · Cited by 119
Lysophosphatidylcholine increases endothelial permeability: role of PKCα and RhoA cross talk
Huang, F., Subbaiah, P. V., Holian, O., Zhang, J., Johnson, A., Gertzberg, N., & Lum, H. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00003.2005 · Cited by 118
Blum, S., Issbrüker, K., Willuweit, A., Hehlgans, S., Lucerna, M., Mechtcheriakova, D., Walsh, K., von der Ahe, D., Hofer, E., & Clauss, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105474200 · Cited by 111
Verrier, E., Wang, L., Wadham, C., Albanese, N., Hahn, C. N., Gamble, J. R., Chatterjee, K., Vadas, M. A., & Xia, P. (2004) · Circulation Research · doi:10.1161/01.res.0000130527.92537.06 · Cited by 117
Self-citationDysfunction of retinal neurons and glia during diabetes
Fletcher, E. L., Phipps, J. A., & Wilkinson‐Berka, J. L. (2005) · Clinical and Experimental Optometry · doi:10.1111/j.1444-0938.2005.tb06686.x · Cited by 116
Gliki, G., ABU-GHAZALEH, R., Jezequel, S., Wheeler-Jones, C. P. D., & Zachary, I. C. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3530503 · Cited by 99
Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors
Frank, R. N. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01321-1 · Cited by 115
RACK1 Regulates VEGF/Flt1-mediated Cell Migration via Activation of a PI3K/Akt Pathway
Wang, F., Yamauchi, M., Muramatsu, M., Osawa, T., Tsuchida, R., & Shibuya, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.165605 · Cited by 114
Enhancement of glucose transport by vascular endothelial growth factor in retinal endothelial cells.
Sone, H., Deo, B. K., & Kumagai, A. K. (2000) · PubMed · Cited by 112
Abid, M. R., Schoots, I. G., Spokes, K. C., Wu, S.-Q., Mawhinney, C., & Aird, W. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408285200 · Cited by 103
Protein kinase C in enhanced vascular tone in diabetes mellitus
Kizub, I. V., Klymenko, K., & Soloviev, A. I. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.04.117 · Cited by 115
“activation of PKC-α, -β [101, 105], -β2 [30], and - [105].”
BackgroundInfluentialAngiogenesis and ophthalmic disease
Adamis, A. P., Aiello, L. P., & D’Amato, R. A. (1999) · Angiogenesis · doi:10.1023/a:1009071601454 · Cited by 109
“Many advances in our understanding of the signaling mechanisms of VEGF have recently been achieved both at the intracellular [36] and nuclear levels [44].”
BackgroundSelf-citationMason, J. C., Yarwood, H., Sugars, K., Morgan, B. P., Davies, K. A., & Haskard, D. O. (1999) · Blood · doi:10.1182/blood.v94.5.1673 · Cited by 100
AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production
Reihill, J. A., Ewart, M.-A., Hardie, D. G., & Salt, I. P. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.110 · Cited by 92
“As VEGF is known to stimulate PLCc-mediated increases in intracellular Ca [3,22] and VEGF-stimulated AMPK activity is inhibited by the PLC inhibitor U73122 (Fig.”
Booth, G., Stalker, T. J., Lefer, A. M., & Scalia, R. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1556 · Cited by 102
Diabetic retinopathy – An update
Alghadyan, A. A. (2011) · Saudi Journal of Ophthalmology · doi:10.1016/j.sjopt.2011.01.009 · Cited by 107
“Activation of protein kinase C causes cellular changes (Xia et al., 1996; Miller et al., 1997), leading to: (a) enhanced permeability of retinal vasculature and alterations in retinal blood flow, (b) basement membrane thickening causing ischemia and cellular signaling by vascular endothelial growth factors (VEGFs) lea…”
BackgroundCunningham, S. A., Arrate, M. P., Brock, T. A., & Waxham, M. N. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7719 · Cited by 105
Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy
Chakrabarti, S., Cukiernik, M., Hileeto, D., Evans, T., & Chen, S. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/1520-7560(0000)9999:9999<::aid-dmrr157>3.0.co;2-g · Cited by 104
“Furthermore, VEGF leads to PKC activation via the VEGFR2, increasing DAG and IP3 levels [196].”
BackgroundCheng, J., Wung, B., Chao, Y., & Wang, D. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011317200 · Cited by 102
Cellular Signaling and Potential New Treatment Targets in Diabetic Retinopathy
Khan, Z. A., & Chakrabarti, S. (2007) · Journal of Diabetes Research · doi:10.1155/2007/31867 · Cited by 100
“Upon binding of VEGF, VEGF-Rs signal the release of DAG (through glycolytic pathway intermediates) [132].”
BackgroundRole of vascular permeability factor/vascular endothelial growth factor in eye disease
Schlingemann, R. O., & van Hinsbergh, V. W. M. (1997) · British Journal of Ophthalmology · doi:10.1136/bjo.81.6.501 · Cited by 102
Mukhopadhyay, D., Nagy, J. A., Manseau, E. J., & Dvorak, H. F. (1998) · PubMed · Cited by 100
Jia, H., Bagherzadeh, A., Bicknell, R., Duchen, M. R., Liu, D., & Zachary, I. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401538200 · Cited by 98
Bradycardia-Induced Coronary Angiogenesis Is Dependent on Vascular Endothelial Growth Factor
Zheng, W., Brown, M. D., Brock, T. A., Bjercke, R. J., & Tomanek, R. J. (1999) · Circulation Research · doi:10.1161/01.res.85.2.192 · Cited by 98
Molecularly targeted therapies for recurrent glioblastoma: current and future targets
Lau, D., Magill, S. T., & Aghi, M. K. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14519 · Cited by 97
Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells
Shimizu, K., Watanabe, K., Yamashita, H., Abé, M., Yoshimatsu, H., Ohta, H., Sonoda, H., & Sato, Y. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.12.073 · Cited by 98
Waterman, R. S., Morgenweck, J., Nossaman, B. D., Scandurro, A. E., Scandurro, S. A., & Betancourt, A. M. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0025 · Cited by 98
Evans, I. M., Britton, G., & Zachary, I. C. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.03.002 · Cited by 96
New Role for the Protein Tyrosine Phosphatase DEP-1 in Akt Activation and Endothelial Cell Survival
Chabot, C., Spring, K., Gratton, J., Elchebly, M., & Royal, I. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01374-08 · Cited by 95
“In response to VEGF stimulation, VEGFR2 activates Src, phosphatidylinositol 3-kinase (PI3K), Akt, and endothelial NO synthase (eNOS), which provide cell survival, migratory, and permeability signals (1, 13, 18, 21, 22, 24, 40, 53 ).”
BackgroundActivation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma
Li, W. (1994) · Oncology Reports · doi:10.3892/or_00000064 · Cited by 95
Davis, M. D., Sheetz, M. J., Aiello, L. P., Milton, R. C., Danis, R. P., Zhi, X., Girach, A., Jimenez, M. C., & Vignati, L. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2473 · Cited by 87
Self-citationEffect of Curcumin on Proliferation of Human Retinal Endothelial Cells under In Vitro Conditions
Premanand, C., Rema, M., Sameer, M. Z., Sujatha, M., & Balasubramanyam, M. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-0580 · Cited by 94
Protein Kinase C and Myocardial Biology and Function
Naruse, K., & King, G. L. (2000) · Circulation Research · doi:10.1161/01.res.86.11.1104 · Cited by 94
Self-citationFGF2 Signaling Is Required for the Development of Neuronal Circuits Regulating Blood Pressure
Dono, R., Faulhaber, J., Galli, A., Zúñiga, A., Volk, T., Texidó, G., Zeller, R., & Ehmke, H. (2002) · Circulation Research · doi:10.1161/hh0102.103611 · Cited by 93
Bursell, S., & King, G. L. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00047-9 · Cited by 94
“Histologically, increases in type IV and VI collagen, fibronectin, and laminin and decreases in proteoglycans are observed in mesangium of diabetic patients [83,84].”
BackgroundSelf-citationKim, M. J., & Lim, Y. (2013) · Mediators of Inflammation · doi:10.1155/2013/510212 · Cited by 92
“This conclusion has been supported by several in vitro experiments [85], which demonstrated that genistein (40 μM) blocked PKC activation in VEGF-stimulated endothelial cells [86].”
ResultTodt, J. C., Hu, B., & Curtis, J. L. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0903439 · Cited by 86
“Based on this reported differential isozyme expression in Mø, the ability of PLC to produce DAG and IP3, and its proven capacity to activate classical PKCs in some cell types [34–36], and as PLC has been shown to be phosphorylated in vitro by a chimeric protein containing the cytoplasmic portion of MerTK [37], we hypo…”
BackgroundCytokines and the Pathogenesis of Macular Edema in Branch Retinal Vein Occlusion
Noma, H., Yasuda, K., & Shimura, M. (2019) · Journal of Ophthalmology · doi:10.1155/2019/5185128 · Cited by 91
Mason, J. C., Yarwood, H., Sugars, K. L., & Haskard, D. O. (1997) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1997.273.4.c1233 · Cited by 91
“The two EC types responded to the different PKC agonists in a very similar manner with respect to morphological changes and enhanced proliferation, consistent with the view that PKC activation is important for endothelial growth during angiogenesis (15, 20, 21, 29, 36).”
BackgroundAdaptive Responses of the Endothelium to Stress
Pohlman, T. H., & Harlan, J. M. (2000) · Journal of Surgical Research · doi:10.1006/jsre.1999.5801 · Cited by 91
Differential Regulation of VEGF Signaling by PKC-α and PKC-ε in Endothelial Cells
Rask‐Madsen, C., & King, G. L. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.162842 · Cited by 89
Self-citationWellner, M., Maasch, C., Kupprion, C., Lindschau, C., Luft, F. C., & Haller, H. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.1.178 · Cited by 78
VEGF stimulates tyrosine phosphorylation of β-catenin and small-pore endothelial barrier dysfunction
Cohen, A. W., Carbajal, J. M., & Schaeffer, R. C. (1999) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1999.277.5.h2038 · Cited by 89
“Endothelial monolayers were pretreated with the selective PKC inhibitor BIM, which prevents the VEGF-dependent increase in PKC activity in BAEC (44).”
BackgroundMethodCan VEGF reverse diabetic neuropathy in human subjects?
Veves, A., & King, G. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13038 · Cited by 88
Self-citationPKC inhibition and diabetic microvascular complications
Clarke, M., & Dodson, P. M. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.09.007 · Cited by 88
Diabetic retinopathy: A comprehensive review
Shah, C. (2008) · Indian Journal of Medical Sciences · doi:10.4103/0019-5359.48562 · Cited by 88
Suzuma, K., Takagi, H., Otani, A., & Honda, Y. (1998) · PubMed · Cited by 88
Self-citationThe zinc-finger transcription factor, early growth response 3, mediates VEGF-induced angiogenesis
Liu, D., Evans, I. M., Britton, G., & Zachary, I. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210959 · Cited by 85
“…production of prostacyclin and nitric oxide, increased cell survival, migration, proliferation and angiogenesis (Waltenberger et al., 1994; Xia et al., 1996; Abedi and Zachary, 1997; Laitinen et al., 1997; Wheeler-Jones et al., 1997; Gerber et al., 1998; AbuGhazaleh et al., 2001; Gliki et…”
BackgroundRole of Inflammation in Diabetic Macular Edema
Noma, H., Mimura, T., Yasuda, K., & Shimura, M. (2014) · Ophthalmologica · doi:10.1159/000364955 · Cited by 85
Suzuma, I., Suzuma, K., Ueki, K., Hata, Y., Feener, E. P., King, G. L., & Aiello, L. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m105336200 · Cited by 85
Self-citationZhang, Y., Jiang, X., Qin, X., Ye, D., Yi, Z., Liu, M., Bai, O., Liu, W., Xie, X., Wang, Z., et al. (2010) · Oncogene · doi:10.1038/onc.2010.270 · Cited by 83
“, 2005), in which tyrosine phosphorylation at 1175 (or 1173 in mouse) activates the phospholipase Cg/protein kinase C pathway, leading to activation of the Raf/MEK/ERK signaling cascade (Guo et al., 1995; Xia et al., 1996; Matsumoto and Mugishima, 2006).”
BackgroundHeo, J. S., Lee, Y. J., & Han, H. J. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00142.2005 · Cited by 83
Antiangiogenic Therapy for Ischemic Retinopathies
Al-Latayfeh, M., Silva, P. S., Sun, J. K., & Aiello, L. P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006411 · Cited by 83
“Several mechanisms have been proposed to explain the pathogenesis of macular edema including hypoxia, inflammatory mediators, renin-angiotensin system, kallikrein-bradykinin system, protein kinase C (PKC), (Xia et al. 1996; Aiello 2002) and VEGF (Aiello et al.”
BackgroundSelf-citationBrawley, L., Poston, L., & Hanson, M. A. (2003) · Archives of Physiology and Biochemistry · doi:10.1076/apab.111.1.23.15138 · Cited by 78
“The endothelium-dependent vasodilator acetylcholine (ACh) mediates vasorelaxation via stimulation of endothelial NO, PGI2 and EDHF (Moncada et al., 1988).”
BackgroundInfluentialAndrikopoulos, P., Baba, A., Matsuda, T., Djamgoz, M. B. A., Yaqoob, M. M., & Eccles, S. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.251777 · Cited by 73
Protein kinase C changes in diabetes: Is the concept relevant to neuropathy?
Eichberg, J. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)50073-8 · Cited by 78
Biochemical Pathways for Microvascular Complications of Diabetes Mellitus
Setter, S. M., Campbell, R. K., & Cahoon, C. J. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d002 · Cited by 78
Kemeny, S. F., Figueroa, D. S., & Clyne, A. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066176 · Cited by 77
“VEGF also enhances PKC activation in a time dependent manner through a PI3K and PLCc mediated pathway [60].”
BackgroundWang, D., Donner, D. B., & Warren, R. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m001847200 · Cited by 76
Watanabe, D., Takagi, H., Suzuma, K., Suzuma, I., Oh, H., Ohashi, H., Kemmochi, S., Uemura, A., Ojima, T., Suganami, E., et al. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63741-8 · Cited by 75
Self-citationNitric Oxide and Angiogenesis in Cardiovascular Disease
Murohara, T., & Asahara, T. (2002) · Antioxidants & Redox Signaling · doi:10.1089/152308602760598981 · Cited by 66
“inositol 3-kinase (PI3K) and phospholipase C (PLC) (56, 58) (Fig.”
Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth.
Cai, W., Rook, S. L., Jiang, Z. Y., Takahara, N., & Aiello, L. P. (2000) · PubMed · Cited by 74
Self-citationPharmacotherapy for diabetic retinopathy
Comer, G. M., & Ciulla, T. A. (2004) · Current Opinion in Ophthalmology · doi:10.1097/01.icu.0000143685.60479.3b · Cited by 71
Xu, X., Zhu, Q., Xia, X., Zhang, S., Gu, Q., & Luo, D. (2004) · Current Eye Research · doi:10.1076/ceyr.28.4.251.27834 · Cited by 74
“VEGF binds to high-affinity receptors on endothelial cells, and then could activate a series of cytoplasmic signaling proteins including phosphatidyl inositol-3 kinase (PI3 kinase), mitogen-activated protein kinase, and PKC.(7,17) Aiello(13) has reported that VEGF induced retinal permeability in the nondiabetic rats c…”
Background
Metadata
- Authors
- Xia, P., Aiello, L. P., Ishii, H., Jiang, Z. Y., Park, D. J., Robinson, G. S., Takagi, H., Newsome, W. P., Jirousek, M. R., & King, G. L.
- Affiliations
- Joslin Diabetes Center (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Eli Lilly (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 1996-11-01
- Volume
- 98
- Issue
- 9
- Pages
- 2018-2026
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC507645
- OpenAlex
- W2075553837
- Cited by
- 566
- References
- 39
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 3 · 2017: 3 · 2016: 9 · 2015: 8 · 2014: 14 · 2013: 21 · 2012: 19
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (5r01dk036433-10, 5r29ey010827-04, 5r01ey005110-18, EY05110)
- National Eye Institute (EY10827, EY05110)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK36433)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- vascular endothelial growth factor, protein kinase C, PKC isoforms, PKC beta, endothelial cell proliferation, signal transduction, phospholipase C-gamma, phosphatidylinositol 3-kinase, diacylglycerol, ruboxistaurin, genistein, wortmannin, bovine aortic endothelial cells
- MeSH terms
- Animals, Cattle, Cell Division, Diglycerides, Endothelium, Vascular, Enzyme Activation, Inositol Phosphates, Isoenzymes, Lymphokines, Type C Phospholipases, Protein Kinase C, Signal Transduction, Endothelial Growth Factors, DNA, Antisense, Phosphotransferases (Alcohol Group Acceptor), Phosphotyrosine, Phosphatidylinositol 3-Kinases, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Phospholipase C gamma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.